关于江苏鹿得医疗电子股份有限公司 使用银行承兑汇票等票据方式支付募投项目所需资金 方正证券承销保荐有限责任公司 并以募集资金等额置换的核查意见 根据《北京证券交易所上市公司持续监管办法（试行）》《证券发行上市保荐 业务管理办法》《北京证券交易所证券发行上市保荐业务管理细则》《北京证券交 易所股票上市规则（试行）》等相关法律、法规和规范性文件的规定，方正证券 承销保荐有限责任公司（以下简称"方正承销保荐"或"保荐机构"）作为江苏 鹿得医疗电子股份有限公司（以下简称"鹿得医疗"或"公司"）向不特定合格 投资者公开发行的保荐机构，对公司使用银行承兑汇票等票据方式支付募投项目 所需资金并以募集资金等额置换的事项进行核查，具体情况如下： 一、募集资金的基本情况 （一）募集资金金额、资金到位时间 根据鹿得医疗 2020 年第二届董事会第十八次会议、2020 年第四次临时股东 大会决议批准，经全国中小企业股份转让系统有限责任公司挂牌委员会审议通过， 并经中国证券监督管理委员会（证监许可[2020]1299 号）文核准，公司向不特定 合格投资者公开发行股票 17,500,000 股，每股面值 1 元，每股发行价人民币 8.5 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥160.60 million, a slight increase of 0.71% compared to ¥159.48 million in the same period last year[24]. - The gross profit margin improved to 28.35%, up from 22.49% in the previous year[24]. - Net profit attributable to shareholders increased by 13.28% to approximately ¥19.80 million, compared to ¥17.48 million in the same period last year[24]. - Basic earnings per share rose to ¥0.1125, reflecting a 13.18% increase from ¥0.0994 in the previous year[24]. - Net profit increased by 14.62% to CNY 19,798,900 compared to the same period last year[27]. - Total operating revenue for the first half of 2023 reached ¥160,599,767.23, a slight increase from ¥159,475,119.82 in the same period of 2022, representing a growth of approximately 0.7%[109]. - Net profit for the first half of 2023 was ¥19,798,936.36, up from ¥17,273,266.18 in the first half of 2022, reflecting a growth of approximately 14.6%[111]. - Earnings per share (EPS) for the first half of 2023 was ¥0.1125, compared to ¥0.0994 in the same period last year, marking an increase of about 11.1%[111]. Investment and Expansion - The company plans to invest approximately ¥1 billion in the "Lude Medical Health Smart Industry Park Project," which will be developed in two phases[2]. - The company is expanding its operations with the establishment of a new research institute and international sales center as part of its new project[2]. - The company has completed the planning design for the factory and plans to officially commence construction in September 2023[81]. - The company has acquired an 84-acre land plot for the "Lude Medical Health Smart Industry Park Project," with a planned total investment of approximately ¥1 billion, to be constructed in two phases[80]. Cash Flow and Assets - Operating cash flow improved significantly, with a net cash flow from operating activities of CNY 12,354,589.37, a 355.68% increase from the previous year[26]. - The company's cash and cash equivalents decreased by 9.44% from the previous year, totaling 166.36 million RMB, which accounted for 37.24% of total assets[43]. - Total assets decreased by 7.43% to CNY 446,724,103.85 compared to the previous year[25]. - Total current assets decreased to CNY 316,753,257.90 as of June 30, 2023, down from CNY 375,755,411.70 at the end of 2022, representing a decline of approximately 15.7%[101]. - Cash and cash equivalents amounted to CNY 166,355,932.44, a decrease from CNY 183,698,966.03, reflecting a reduction of about 9.1%[101]. Liabilities and Equity - Total liabilities decreased by 26.01% to CNY 68,944,734.07 compared to the previous year[25]. - Shareholders' equity decreased to CNY 377,779,369.78 from CNY 389,390,433.42, reflecting a decrease of about 3.0%[103]. - The company reported a total equity attributable to shareholders of 389,390,433.42 at the end of the period, down from 362,836,892.80, indicating an increase of about 7.3%[119]. Research and Development - The company completed 7 out of 20 R&D and technical improvement projects during the reporting period[38]. - Research and development expenses increased by 14.42% to CNY 6,696,307.54, indicating a focus on innovation and product development[47]. - The company is committed to continuous R&D of new technologies and products to adapt to market changes and customer demands[70]. Market Performance - Sales in the South American market doubled, with significant growth in nebulizers and electronic blood pressure monitors[37]. - Cross-border e-commerce sales increased by 208%, with the addition of the EBAY platform[37]. - Domestic sales revenue grew by 50.33%, primarily due to increased demand for nebulizers and pulse oximeters in the domestic market[55]. Risks and Challenges - The company faces a risk of reduced overseas sales, which account for approximately 80% of total revenue, due to macroeconomic changes and international conflicts[68]. - The fluctuation in raw material prices poses a significant risk, as direct materials constitute a high proportion of the main business costs[68]. - The foreign exchange rate fluctuations could significantly impact the company's profitability, as approximately 80% of sales revenue comes from overseas[68]. - The company is at risk of losing market share in mechanical sphygmomanometers to electronic blood pressure monitors, which are gaining popularity due to technological advancements[70]. Corporate Governance - The report indicates that there were no objections from directors or supervisors regarding the accuracy of the financial report[8]. - The company has established a sound corporate governance structure to ensure compliance with relevant laws and regulations[69]. - The board of directors consists of 7 members, with no changes in the chairman or general manager positions during the reporting period[95]. Legal Matters - The company has ongoing litigation involving a total amount of 6,292,189.56 yuan, which represents 1.67% of its net assets, but these are considered normal business disputes[75]. - The company is involved in a legal dispute with Sunshine Property Insurance Co., Ltd., with a court ruling requiring the insurer to compensate the company for losses amounting to ¥1,137,045.59[77]. - There are no significant litigation or arbitration matters concluded during the reporting period[78]. Human Resources - The total number of employees increased from 554 to 595, with a net addition of 48 employees during the reporting period[96]. - The proportion of employees with a bachelor's degree increased from 89 to 93, while those with below a college degree rose from 355 to 400[96]. - The company acknowledges the need for improved management and human resources to support rapid business expansion in the future[69].

Company Achievements and Recognition - The company received a medical device registration certificate for its electronic stethoscope, with registration number 苏械注准 20222070009[4] - The company was recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise by Jiangsu Province, receiving 3 million yuan in funding support[4] - The company has been recognized as a "National Intellectual Property Demonstration Enterprise" for its commitment to innovation[4] - The company completed the acquisition of 100% ownership in Shanghai Lude Mountain Medical Equipment Co., Ltd. in August 2022, enhancing its strategic positioning[83] - The company has received a high-tech enterprise certificate, allowing it to apply a 15% corporate income tax rate[84] Financial Performance - The company's operating revenue for 2022 was ¥338,994,316, a decrease of 15.85% compared to ¥402,846,212.58 in 2021[29] - The net profit attributable to shareholders for 2022 was ¥34,872,417.98, down 8.56% from ¥38,137,789.78 in 2021[29] - The gross profit margin improved to 24.47% in 2022 from 23.25% in 2021[29] - The basic earnings per share decreased to 0.20 in 2022, a decline of 9.09% from 0.22 in 2021[29] - The weighted average return on equity based on net profit attributable to shareholders was 9.27% in 2022, down from 10.27% in 2021[29] - Net profit for 2022 was CNY 34.64 million, down 8.82% year-over-year, while total revenue decreased by 15.85% to CNY 338.99 million[47] - The company's net assets increased by 7.36% to CNY 389.39 million compared to CNY 362.68 million in 2021[31] - The interest coverage ratio was 135.46 in 2022, down from 209.33 in 2021[35] Research and Development - The company has established a core technology team led by the R&D director to maintain its competitive advantage in the market[11] - The company applied for 39 patents in 2022, bringing the total number of authorized patents to 88, including 8 invention patents[48] - Research and development expenses increased by 5.04% to CNY 13,636,169.92, representing 4.02% of total revenue[58] - The company is in the identification and evaluation phase for several R&D projects, including a high-end stethoscope and a noise-reducing nebulizer[91] - The company aims to enhance its product development in innovative medical devices, focusing on areas such as imaging and wearable monitoring technologies[52] Market and Sales - Sales revenue from overseas customers accounted for over 80% of total sales, exposing the company to risks from macroeconomic changes and international conflicts[10] - The company achieved a gross margin of 24.47% in 2022, up from 23.25% in the previous year[47] - Sales of nebulizers increased by 16% year-over-year, with significant growth in Western Europe and South America[48] - Revenue from cross-border e-commerce on Amazon grew over 400%, while sales on Alibaba's international platform increased by over 500%[48] - The company’s products primarily export to the US and European markets, indicating a strong international presence[191] Risks and Challenges - The company faces risks from fluctuations in raw material prices, which significantly impact its main business costs and profitability[10] - The company is subject to risks related to inventory impairment due to potential changes in customer orders and market conditions[11] - The company faces risks related to new product and technology development, which require significant time and resources[12] - There is a risk of market share loss for mechanical sphygmomanometers due to the increasing adoption of electronic blood pressure monitors[12] - The company faces risks from high reliance on overseas customers, with over 80% of sales revenue coming from international markets[108] Corporate Governance and Shareholder Relations - The company’s actual controllers hold a combined 57.04% of voting rights, which may pose risks if decisions conflict with the interests of other shareholders[11] - The company has established a governance structure in compliance with relevant laws and regulations to mitigate risks associated with actual controllers[114] - The company has committed to measures to protect the legitimate interests of small and medium investors by ensuring that the dilution of immediate returns is compensated through business growth and profitability improvements[143] - The company aims to maintain a transparent and sustainable profit distribution mechanism to enhance shareholder confidence[138] - The company has a well-defined internal control system to ensure the accuracy of financial reporting and operational management[112] Strategic Goals and Future Plans - The company continues to focus on expanding its product offerings and enhancing its competitive edge in the medical device industry[12] - The company plans to enhance its product system and expand into new application areas for nebulized drug delivery as part of its strategic goals[104] - The company aims to increase its research and development investment and improve its innovation capabilities to support the expansion of its product system[104] - The company is focusing on integrating high-quality assets in the industry to enhance overall synergy and product line strategy[105] - The company plans to invest approximately RMB 1 billion in the "Lude Medical Health Smart Industry Park Project," which includes a research institute and production base, with equipment investment around RMB 400 million[172]

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 12.30 million, representing a significant increase of 48.39% year-over-year[11]. - Operating revenue for the first quarter of 2023 was CNY 79.58 million, up 4.35% from CNY 76.26 million in the same period last year[11]. - The net cash flow from operating activities improved to CNY 20.01 million, a 173.66% increase compared to a net outflow of CNY 27.17 million in the previous year[11]. - Total revenue for Q1 2023 reached ¥79,581,657.02, an increase of 4.3% compared to ¥76,264,998.06 in Q1 2022[39]. - Net profit for Q1 2023 was ¥12,301,975.66, representing a significant increase of 60.5% from ¥7,695,420.23 in Q1 2022[41]. - Operating profit for Q1 2023 was ¥12,104,156.29, a significant increase of 187.5% compared to ¥4,203,364.57 in Q1 2022[45]. - The total comprehensive income for Q1 2023 was ¥11,015,825.86, reflecting a substantial increase from ¥3,642,258.77 in Q1 2022[45]. Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 495.70 million, an increase of 2.72% compared to the end of 2022[11]. - The company's asset-liability ratio (consolidated) decreased to 18.97% from 19.31% at the end of 2022[11]. - The total liabilities of the company stood at CNY 94,011,706.94 as of March 31, 2023, compared to CNY 93,170,485.25 at the end of 2022, showing a slight increase of about 0.9%[33]. - The company's total equity increased to CNY 401,692,409.08 as of March 31, 2023, from CNY 389,390,433.42 at the end of 2022, marking an increase of approximately 3.2%[33]. - The company's total assets as of March 31, 2023, amounted to ¥465,562,155.65, compared to ¥456,349,751.20 at the end of 2022, indicating a growth of 2.6%[37]. - The company's total liabilities decreased to ¥76,173,185.29 from ¥77,976,606.70, a reduction of 2.3%[37]. Cash Flow - Cash flow from operating activities for Q1 2023 was ¥20,011,563.46, a turnaround from a negative cash flow of ¥27,166,252.58 in Q1 2022[46]. - Cash and cash equivalents at the end of Q1 2023 totaled ¥193,307,419.41, compared to ¥177,993,134.27 at the end of Q1 2022[48]. - The net increase in cash and cash equivalents was $7.85 million, a recovery from a decrease of $22.78 million in the previous period[50]. - The ending balance of cash and cash equivalents was $171.33 million, up from $163.48 million at the beginning of the period, indicating improved liquidity[50]. Shareholder Information - The total number of shares outstanding is 176,000,000, with 41.47% being unrestricted shares held by controlling shareholders[18]. - The top five shareholders collectively hold 71.61% of the total shares, with the largest shareholder, Xiang Youliang, owning 22.23%[21]. - The company has 7,227 common shareholders as of the end of the reporting period[18]. - There were no changes in the number of restricted shares during the reporting period, remaining at 103,011,600, which constitutes 58.53% of total shares[18]. Expenses - Sales expenses for Q1 2023 were CNY 4.54 million, up 32.93% year-over-year, driven by increased export sales and marketing efforts[15]. - Research and development expenses for Q1 2023 were ¥2,179,698.65, a decrease of 25.7% from ¥2,934,807.32 in Q1 2022[41]. - Sales expenses increased to ¥2,942,959.74 in Q1 2023, up 91.1% from ¥1,540,836.65 in Q1 2022[44]. Legal and Compliance - The company reported no significant litigation or arbitration matters that would impact its financial position[25]. - The company has complied with all internal review procedures for significant matters during the reporting period[24]. - The company has not engaged in any share buyback activities during the reporting period[24]. - The company has fulfilled all previously disclosed commitments in a timely manner[24]. - The company is currently involved in a legal dispute with Sunshine Property Insurance Co., Ltd., with a claim for compensation amounting to CNY 1,137,045.59[26]. Investments - Investment income surged by 765.72% to CNY 2.79 million, attributed to strong performance from associated enterprises[15]. - The company has projected a total of CNY 10,700,000 for related party transactions in 2023, with actual transactions in the first quarter amounting to CNY 2,572,949, which is about 24% of the projected total[29]. - Non-recurring gains and losses for the period totaled CNY 249.82 million, with a net amount of CNY 222.30 million after tax impacts[16].

Financial Performance - The total operating revenue for the reporting period was approximately ¥339.38 million, a decrease of 15.75% compared to the previous year[3] - The net profit attributable to shareholders was approximately ¥36.58 million, down 4.08% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥35.50 million, an increase of 12.59% year-on-year[3] - The basic earnings per share were ¥0.21, a decrease of 4.55% compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were approximately ¥483.38 million, a slight increase of 0.05% year-on-year[4] - Shareholders' equity attributable to the company was approximately ¥391.14 million, an increase of 7.85% year-on-year[4] Operational Challenges - The decline in operating revenue was primarily due to disruptions in the supply chain caused by recurring domestic COVID-19 outbreaks and geopolitical tensions[5] Financial Data Caution - The company emphasizes that the financial data is preliminary and has not been audited, urging investors to be cautious[6] - The final data will be disclosed in the company's 2022 annual report[6] Profitability - The company's gross profit margin slightly increased due to effective cost control and exchange rate gains despite a decline in revenue[5]

证券代码：832278 证券简称：鹿得医疗 公告编号：2022-089 江苏鹿得医疗电子股份有限公司 关于接待机构投资者调研情况的公告 | --- | --- | |------------------------------------------------------------------------|-------| | | | | 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 | | | 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 | | | 带法律责任。 | | 江苏鹿得医疗电子股份有限公司（以下简称"公司"）于 2022 年 11 月 18 日接待了 33 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2022 年 11 月 18 日 调研形式：网络调研 调研机构：凯丰投资、建信保险资产管理有限公司、上海混沌投资（集团） 有限公司、上海尚近投资管理合伙企业（有限合伙）、东北证券、财信证券、上 海东证期货有限公司、开源证券、兴证资产管理有限公司、渤海证券、九泰基金、 红塔证券、淡马锡富敦投资有限公司、交银理财、华福证券有限责任 ...

Financial Performance - Net profit attributable to shareholders for the first nine months of 2022 was CNY 27,983,931.23, down 16.85% from CNY 33,654,862.00 in the same period last year[14] - Operating income for the third quarter of 2022 was CNY 79,321,240.17, a decrease of 6.16% compared to CNY 84,530,290.27 in the third quarter of 2021[15] - Total operating revenue for 2022 was CNY 79,321,240.17, a decrease from CNY 84,530,290.27 in 2021, representing a decline of approximately 14.5%[50] - Operating profit for 2022 was CNY 12,528,738.42, compared to CNY 10,820,053.06 in 2021, showing an increase of approximately 15.8%[51] - Total profit for Q3 2022 was ¥12,956,172.46, compared to ¥8,166,114.36 in Q3 2021, marking an increase of approximately 58.5%[56] - Net profit for Q3 2022 was ¥11,724,611.31, compared to ¥7,368,150.24 in Q3 2021, indicating a significant increase of about 59.5%[56] Assets and Liabilities - Total assets as of September 30, 2022, were CNY 469,487,978.68, a decrease of 2.83% compared to the end of the previous year[14] - The company's total liabilities to assets ratio decreased to 18.48% from 24.90% year-on-year[14] - The balance of trading financial assets increased by 1,387.65% to CNY 22,319,846.80 due to investments in low-risk financial products[16] - The balance of short-term loans increased by 100% to CNY 1,000,188.89, reflecting the company's strategy to enhance short-term liquidity[16] - The total liabilities decreased from 120,322,340.34 yuan at the end of 2021 to 86,753,924.53 yuan by September 30, 2022[44] - Current liabilities decreased from CNY 107,647,995.92 to CNY 74,085,226.27, reflecting a reduction of approximately 31.2%[48] Cash Flow - The company's cash flow from operating activities increased by 262.76% to CNY 14,623,600.62 in the third quarter of 2022, compared to a negative cash flow of CNY 8,985,002.94 in the same period last year[15] - Net cash flow from operating activities was CNY 9,791,528.46, up from CNY 5,921,715.03 year-over-year[60] - Cash inflow from operating activities totaled CNY 280,527,634.84, while cash outflow was CNY 270,736,106.38, resulting in a net cash flow of CNY 9,791,528.46[60] - Cash flow from investment activities showed a net outflow of CNY 43,514,417.01, compared to a net inflow of CNY 44,482,868.54 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY 5,356,277.00, down from a net inflow of CNY 13,100,000.00 in the previous year[60] Shareholder Information - Total shares outstanding are 176,000,000, with 72,988,400 shares (41.47%) being unrestricted and 103,011,600 shares (58.53%) being restricted[28] - The largest shareholder, Xiang Youliang, holds 39,130,000 shares, representing 22.23% of total shares[30] - The second largest shareholder, Shanghai Lude Industrial Development Co., Ltd., holds 38,944,000 shares, accounting for 22.13%[30] - The company has a total of 7,913 common stock shareholders[28] Research and Development - Research and development expenses for 2022 were CNY 9,609,396.31, up from CNY 8,667,604.26 in 2021, indicating an increase of about 10.9%[51] - Research and development expenses for the first nine months of 2022 totaled ¥9,609,396.31, an increase from ¥8,667,604.26 in the same period of 2021, showing a growth of about 10.8%[55] Other Income and Expenses - Other income for the first nine months of 2022 was ¥3,704,407.43, an increase of 461.37% compared to the same period last year, mainly due to government subsidies received in September 2022[22] - Financial expenses for the first nine months of 2022 were -¥11,454,795.66, a decrease of 993.98% compared to the same period last year, primarily due to exchange rate gains[22] - The income tax expense for the first nine months of 2022 was ¥3,278,613.02, a decrease of 32.37% compared to the same period last year, mainly due to changes in R&D tax deduction policies[22] Legal and Compliance - The company is involved in a legal dispute with Sunshine Property Insurance Co., Ltd. regarding a compensation claim of 1,137,045.59 yuan[36] - The company has reported no significant adverse effects from ongoing litigation, which is considered normal for business operations[35] - The company has disclosed its compliance with internal review procedures for significant events during the reporting period[34]

Recognition and Support - The company was recognized as a "specialized, refined, and innovative" small giant enterprise by the Jiangsu Provincial Department of Industry and Information Technology in January 2022[5]. - The company received a funding support of 3 million yuan for the "specialized, refined, and innovative" small giant enterprise cultivation project in June 2022[5]. - The company received support from the Jiangsu Provincial Department of Finance for its industrial transformation and upgrading project[5]. Product Development and Innovation - The company obtained the medical device registration certificate for its electronic stethoscope in January 2022, with registration number 苏械注准 20222070009[6]. - The company has established a core technical team led by the R&D director to maintain its competitive advantage in product development[13]. - The company emphasizes the importance of continuous investment in new technology research and product development to maintain competitiveness in a rapidly evolving market[14]. - The company holds 83 authorized patents, including 7 invention patents, which supports its ongoing operations and technological advancements[43]. - The company is focused on enhancing its research and development capabilities to maintain product competitiveness and profit levels[77]. - The company plans to increase investment in product and technology development to enhance innovation capabilities and core competitiveness[108]. Financial Performance - The company's revenue for the current period is 159.48 million, a decrease of 19.02% compared to the same period last year, which was 196.92 million[32]. - The net profit attributable to shareholders for the current period is 17.48 million, down 26.14% from 23.67 million in the same period last year[32]. - The gross profit margin for the current period is 22.49%, compared to 24.03% in the previous year[32]. - The total assets at the end of the current period amount to 489.39 million, reflecting a growth of 1.29% from 483.16 million at the end of the previous year[33]. - The total liabilities decreased by 4.54% to 114.86 million from 120.32 million year-over-year[33]. - The net cash flow from operating activities for the current period is -4.83 million, a decline of 132.42% compared to 14.91 million in the same period last year[34]. - The company reported a significant decline in profit margins due to increased raw material costs and reduced order volumes influenced by external factors such as the pandemic and geopolitical tensions[43]. Market Exposure and Risks - Over 86% of the company's sales revenue comes from overseas customers, exposing it to risks from trade tensions and increased market access barriers[12]. - The company faces significant risks from fluctuations in raw material prices, which constitute a high proportion of its main business costs[12]. - The company’s foreign sales revenue accounted for over 80% of its total revenue during the reporting period, making it vulnerable to foreign exchange rate fluctuations[12]. - The company is at risk of inventory impairment due to potential changes in customer order fulfillment and market conditions[13]. - The company faces management risks due to the need for talent acquisition in technology, management, and marketing to support rapid business expansion[14]. - The company is at risk of technological obsolescence as mechanical sphygmomanometers, its largest revenue-generating product, may lose market share to electronic blood pressure monitors[14]. - The company faces significant risks from raw material price volatility, which can directly impact its main business costs and profitability[76]. - The company is actively expanding domestic sales channels to mitigate risks associated with overseas sales and international shipping challenges[77]. Governance and Shareholder Relations - The company has established a governance structure and operational system suitable for its current scale, but rapid expansion will require higher resource integration and market development capabilities[14]. - The company’s actual controllers hold a combined 29.91% of the shares, which may pose risks related to improper control[13]. - The company controls 57.04% of the voting rights through indirect control of 5.00% shares by Lujing Investment[14]. - The actual controllers hold a combined 57.04% voting rights, which poses a risk of decisions that may not align with the interests of the company and other shareholders[81]. - The company has established a shareholder return plan, ensuring that cash dividends distributed in a single year are not less than 10% of the distributable profits for that year[106]. - The company commits to distributing no less than 30% of the average annual distributable profits over the last three years in cash dividends[106]. - The actual controllers of the company have issued irrevocable commitments to avoid competition and conflicts of interest, ensuring the company's interests are safeguarded[112]. - The company has made commitments to regulate and reduce related party transactions to enhance governance and protect shareholder interests[113]. Operational Challenges and Changes - The company is at risk of inventory impairment due to potential changes in customer order fulfillment and market conditions[13]. - The company has established a plan to address risks associated with its operations, including relocation risks[99]. - The company has postponed the construction period for the medical device products and accessories smart upgrade project from 18 months to 48 months, and the R&D center construction project from 24 months to 48 months, both expected to reach the predetermined usable state by July 2024[130]. - The company is actively analyzing the feasibility of relocating the implementation address for the smart upgrade project and R&D center[133]. - The company has suspended the approval procedures for new industrial land projects in the Nantong Economic Development Zone, affecting the R&D center construction project[133]. Employment and Social Responsibility - Company has absorbed 5 individuals from targeted poverty alleviation households, promoting employment stability[73]. - The company is committed to social responsibility, contributing to local economic development and creating job opportunities for residents and disabled individuals[74]. - The actual controllers have committed to ensuring compliance with social insurance and housing fund contributions for employees, taking responsibility for any potential penalties or losses[115]. Legal and Compliance Matters - The company has no significant litigation or arbitration matters during the reporting period, indicating stable operational conditions[89]. - The total amount involved in ongoing litigation is 6,292,189.56 yuan, representing 1.68% of the company's net assets, which is not expected to adversely affect ongoing operations[88]. - The company has disclosed ongoing litigation related to property damage claims, with a claim amount of 1,137,045.59 yuan, which is not considered significant[90]. Financial Management and Fundraising - The company raised a total of 149,625,000 yuan from a public offering in 2020, with specific allocations for various projects[129]. - The company has established a dedicated account for managing the raised funds to ensure compliance with disclosed purposes[129]. - The company plans to use up to 1.2 billion yuan of idle raised funds for purchasing financial products with high safety and liquidity[129]. - The company has implemented a fundraising management system to ensure the legal and compliant use of raised funds[109]. - The company is committed to improving governance and operational efficiency to maximize shareholder rights and enhance internal management[109].

Industry Standards and Innovations - The company participated in the formulation of the national medical industry standard for stethoscopes, which was officially implemented on April 1, 2022[7]. - The company has obtained a total of 7 authorized invention patents, showcasing its innovation capabilities in electronic stethoscope applications[9]. - The infrared forehead thermometer received FDA 510(K) approval, indicating compliance with U.S. regulatory standards[10]. - The company completed the research and development of 24 new projects, resulting in a total of 74 authorized patents by the end of the reporting period[53]. - Beirui Electronic has obtained over 20 patents and software copyrights, and its products have been certified by FDA, CE, and NMPA[139]. Financial Performance - The company's operating revenue for 2021 was ¥402,846,212.58, a decrease of 3.02% compared to ¥415,375,455.49 in 2020[36]. - The net profit attributable to shareholders for 2021 was ¥38,137,789.78, representing a decline of 29.80% from ¥54,329,062.88 in 2020[36]. - The gross profit margin for 2021 was 23.25%, down from 27.33% in 2020[36]. - Total profit was 43.04 million yuan, down 33.65% year-on-year, while net profit was 37.99 million yuan, a decline of 30.07%[52]. - The company's cash flow from operating activities decreased by 71.88% to ¥18,916,695.52 in 2021, down from ¥67,265,066.26 in 2020[40]. Market Exposure and Risks - Over 80% of the company's sales revenue comes from overseas clients, exposing it to risks from international trade tensions and regulatory changes[17]. - The company is exposed to foreign exchange risks, as over 80% of its sales revenue is generated from international markets, primarily settled in USD[18]. - The fluctuation in raw material prices significantly impacts the company's main business costs, with direct materials accounting for a high proportion of costs[17]. - The company faces risks related to inventory impairment as it expands its production scale, which may lead to a decrease in the net realizable value of inventory[18]. - The company is at risk of operational challenges due to the relocation of its subsidiary's production site, which has unresolved property rights issues[18]. Strategic Investments and Partnerships - The company invested RMB 20.2136 million to acquire a 22% stake in Beirui Electronics, enhancing its strategic position in the market[8]. - The company established a joint laboratory with Shanghai University to conduct research on digital therapies for cardiovascular and respiratory diseases[11]. - The company plans to enhance its market presence through the development of a visualized intelligent breathing trainer in collaboration with Shanghai University[98]. - The company plans to expand its market presence and enhance product offerings through strategic investments and partnerships[78]. Shareholder and Governance Matters - The actual controllers of the company hold a total of 57.04% of the voting rights, with Xiang Youliang, Huang Jiejing, and Xiang Guoqiang directly holding 29.91% and indirectly controlling an additional 22.13%[19]. - The company has committed to a transparent profit distribution policy to protect the rights of shareholders, especially minority shareholders[154]. - The company will implement measures to mitigate risks associated with potential relocations of its operations due to property issues[159]. - The company has established a governance structure to ensure shareholders can fully exercise their rights and improve operational efficiency[153]. Employee and Social Responsibility - The company has absorbed 14 employees from targeted poverty alleviation households, promoting skill development through internal apprenticeship programs[107]. - The company actively supports social responsibility initiatives, contributing materials to the Nantong Development Zone Charity Association[108]. - The company has implemented a training program for employees to enhance their skills and capabilities[194]. - The company reported a total of 729 employees at the end of the period, an increase of 69 employees from the beginning of the period[193]. Market Trends and Future Outlook - The home medical device market is expected to grow significantly due to increasing consumer demand and an aging population[54]. - The medical device industry is experiencing steady growth, driven by increasing health awareness and demand for medical services globally[109]. - The global medical device market is projected to grow from $405 billion in 2017 to $594.5 billion by 2024, with a CAGR of 5.6%[110]. - China's medical device market sales increased from 81.2 billion yuan in 2009 to 530.4 billion yuan in 2018, achieving a CAGR of 23.19%[111].

Financial Performance - Operating revenue for the first quarter of 2022 was CNY 76,264,998.06, down 14.21% year-on-year[17] - Net profit attributable to shareholders for the first quarter of 2022 was CNY 8,290,521.47, a decline of 38.48% compared to the same period last year[17] - The decline in net profit was primarily attributed to the impact of recurring domestic and international pandemic conditions affecting order shipments[18] - Basic earnings per share for the first quarter of 2022 were CNY 0.05, down 58.33% from CNY 0.12 in the same period last year[17] - Total operating revenue for Q1 2022 was ¥76,264,998.06, a decrease of 14.3% compared to ¥88,901,410.56 in Q1 2021[45] - Net profit for Q1 2022 was ¥7,695,420.23, a decline of 42.3% from ¥13,476,472.89 in Q1 2021[48] - The net profit for Q1 2022 was CNY 3,642,258.77, a decrease of 47.5% compared to CNY 6,923,973.83 in Q1 2021[52] - The total profit before tax was CNY 4,201,368.86, down from CNY 7,977,252.24 in Q1 2021, representing a decline of 47.3%[52] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 107.91% year-on-year, amounting to CNY -27,166,252.58[17] - Cash flow from operating activities showed a negative trend, with a net cash outflow indicating potential operational challenges[58] - The cash inflow from sales of goods and services was CNY 82,659,652.38, an increase from CNY 79,855,546.98 in Q1 2021, reflecting a growth of 3.5%[54] - The cash flow from operating activities showed a net outflow of CNY 27,166,252.58, compared to a smaller outflow of CNY 13,066,138.99 in Q1 2021[54] - The ending cash and cash equivalents balance was $166.2 million, down from $124.7 million year-over-year, indicating a decrease in liquidity[58] - The net increase in cash and cash equivalents was -$22.8 million, contrasting with a positive increase of $22.3 million in the previous period[58] - The company recorded interest income of CNY -551,877.52, which reflects a significant increase in interest expenses compared to CNY -208,462.37 in the previous year[52] Assets and Liabilities - Total assets as of March 31, 2022, were CNY 466,045,138.52, a decrease of 3.54% compared to the end of the previous year[17] - The company's total liabilities decreased to 95,452,885.92 yuan from 120,322,340.34 yuan, reflecting a reduction of approximately 20.7%[38] - The company's equity attributable to shareholders increased to 370,650,110.38 yuan from 362,683,642.86 yuan, showing a growth of about 2.7%[38] - Total assets decreased to ¥423,620,991.23 in 2022 from ¥455,833,689.79 in 2021, indicating a reduction in asset base[43] - Total liabilities decreased to ¥73,371,851.35 in 2022 from ¥110,852,710.56 in 2021, showing improved financial leverage[43] Shareholder Information - The total registered capital of the company is CNY 176,000,000[15] - The company reported a total shareholding of 126,618,500 shares, representing 71.95% of the total shares outstanding[26] - Major shareholders include Xiang Youliang with 22.23%, Shanghai Lude Industrial Development Co., Ltd. with 22.13%, and Xiang Guoqiang with 5.82%[26] - The company has a total of 39,130,000 shares held by Xiang Youliang, which is unchanged from the previous period[26] - The company has a total of 10,238,400 shares held by both Xiang Guoqiang and Zhu Zengkai, each representing 5.82%[26] - The company reported a decrease of 2,000 shares held by shareholder Tan Wei Ying, bringing her total to 3,321,200 shares[26] Operational Challenges - The company experienced a rise in raw material procurement costs, leading to increased sales costs and a decline in gross profit margin[19] - The company reported a loss of 1,307,559.96 yuan due to a fire caused by a battery leak, with an additional 50,000.00 yuan paid for assessment fees[31] - The company has ongoing litigation with Sunshine Property Insurance Co., seeking compensation of 1,357,559.96 yuan for the fire incident[31] - The company has no significant assets under seizure, freezing, or mortgage during the reporting period[29] - There were no significant lawsuits or arbitration matters reported during the period[30] Compliance and Governance - The company has maintained compliance with internal review procedures for related party transactions[29] - The company disclosed no profit distribution or capital reserve transfer during the reporting period[33] - The company has no external guarantees or loans provided during the reporting period[29] - The company has conducted share buybacks, with announcements made in 2022[29]